Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma
Science Translational Medicine · 28.06.2023 · 15 (702)
DOI: 10.1126/scitranslmed.abo3826 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 28.06.2023. Verfasst von Cristina Mastini und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino 10126, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Lymphoma, Large-Cell, Anaplastic. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) show potent efficacy in several ALK-driven tumors, but the development of resistance limits their long-term clinical impact. Although resistance mechanisms have been studied extensively in ALK-driven non–small cell lung cancer, they are poorly understood in ALK-driven anaplastic large cell lymphoma (ALCL). Here, we identify a survival pathway supported by the tumor microenvironment that activates phosphatidylinositol 3-kinase γ (PI3K-γ) signaling through the C-C motif chemokine receptor 7 (CCR7). We found increased PI3K signaling in patients and ALCL cell lines resistant to ALK TKIs. PI3Kγ expression was predictive of a lack of response to ALK TKI in patients with ALCL. Expression of CCR7, PI3Kγ, and PI3Kδ were up-regulated during ALK or STAT3 inhibition or degradation and a constitutively active PI3Kγ isoform cooperated with oncogenic ALK to accelerate lymphomagenesis in mice. In a three-dimensional microfluidic chip, endothelial cells that produce the CCR7 ligands CCL19/CCL21 protected ALCL cells from apoptosis induced by crizotinib. The PI3Kγ/δ inhibitor duvelisib potentiated crizotinib activity against ALCL lines and patient-derived xenografts. Furthermore, genetic deletion of CCR7 blocked the central nervous system dissemination and perivascular growth of ALCL in mice treated with crizotinib. Thus, blockade of PI3Kγ or CCR7 signaling together with ALK TKI treatment reduces primary resistance and the survival of persister lymphoma cells in ALCL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino 10126, Italy.
- Dana Farber Cancer Institute, Boston, MA 02115, USA.
- Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.
- Department of Mechanical and Aerospace Engineering, Politecnico of Torino, Torino 10129, Italy.
- Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston MA 02115, USA.
- Department of Oncology, University of Torino, Orbassano, Torino 10043, Italy.
ORCID-Profile: Cristina Mastini, Marco Campisi, Enrico Patrucco, Antonio Ferreira, Chiara Ambrogio, Giulia Germena, Ines Mota, Elena Vissio, Maddalena Arigoni, Nina Prokoph, Fabrizio Tabbò, Brent Shoji, Laurence Brugieres, Birgit Geoerger, Suzanne D Turner, Deborah D'Aliberti, Luca Mologni, Rocco Piazza, Valeria Chiono, Roger D Kamm, Emilio Hirsch, Raphael Koch, David M Weinstock, Claudia Voena, Roberto Chiarle
Förderung
- NCI NIH HHS
Zitieren
APA
Mastini, C., Campisi, M., Patrucco, E., Mura, G., Ferreira, A., Costa, C., Ambrogio, C., Germena, G., Martinengo, C., Peola, S., Mota, I., Vissio, E., Molinaro, L., Arigoni, M., Olivero, M., Calogero, R., Prokoph, N., Tabbò, F., Shoji, B., …, & Chiarle, R. (2023). Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma. Science Translational Medicine, 15(702). https://doi.org/10.1126/scitranslmed.abo3826
Vancouver
Mastini C, Campisi M, Patrucco E, Mura G, Ferreira A, Costa C, et al. Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma. Science Translational Medicine. 2023;15(702). doi:10.1126/scitranslmed.abo3826
BibTeX
@article{Mastini2023,
author = {Mastini, Cristina and Campisi, Marco and Patrucco, Enrico and Mura, Giulia and Ferreira, Antonio and Costa, Carlotta and Ambrogio, Chiara and Germena, Giulia and Martinengo, Cinzia and Peola, Silvia and Mota, Ines and Vissio, Elena and Molinaro, Luca and Arigoni, Maddalena and Olivero, Martina and Calogero, Raffaele and Prokoph, Nina and Tabbò, Fabrizio and Shoji, Brent and Brugieres, Laurence and Geoerger, Birgit and Turner, Suzanne D and Cuesta-Mateos, Carlos and D'Aliberti, Deborah and Mologni, Luca and Piazza, Rocco and Gambacorti-Passerini, Carlo and Inghirami, Giorgio G and Chiono, Valeria and Kamm, Roger D and Hirsch, Emilio and Koch, Raphael and Weinstock, David M and Aster, Jon C and Voena, Claudia and Chiarle, Roberto},
title = {Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma},
journal = {Science Translational Medicine},
year = {2023},
volume = {15},
number = {702},
doi = {10.1126/scitranslmed.abo3826}
}
EUVIMED